KAPA · Kairos Pharma Ltd. Common Stock
View on chartInsiders & Stakes
| Bhowmick Neil Chief Scientific Officer | ▲ Buy | Grant | 1,311,739 Shares held | 10/8/2025 | View profile |
| Murali Ramachandran VP of Research and Development | ▲ Buy | Grant | 299,529 Shares held | 10/8/2025 | View profile |
| Samuelson Doug Chief Financial Officer | ▲ Buy | Grant | 293,039 Shares held | 10/8/2025 | View profile |
| Yu John S CEO and Chairman | ▲ Buy | Grant | 230,105 Shares held | 10/8/2025 | View profile |
| Bae Hyun W. Director | ▲ Buy | Grant | 73,370 Shares held | 10/8/2025 | View profile |
| Rahul Singhvi Director | ▲ Buy | Grant | 49,204 Shares held | 10/8/2025 | View profile |
| Keyoung Hansoo Michael Director | ▲ Buy | Grant | 29,084 Shares held | 10/8/2025 | View profile |
Transaction History
| Bhowmick Neil | ▲ Buy | Grant | 171,756 | $0 | 10/8/2025 |
| Bae Hyun W. | ▲ Buy | Grant | 19,084 | $0 | 10/8/2025 |
| Murali Ramachandran | ▲ Buy | Grant | 152,672 | $0 | 10/8/2025 |
| Keyoung Hansoo Michael | ▲ Buy | Grant | 19,084 | $0 | 10/8/2025 |
| Rahul Singhvi | ▲ Buy | Grant | 19,084 | $0 | 10/8/2025 |
| Samuelson Doug | ▲ Buy | Grant | 152,672 | $0 | 10/8/2025 |
| Yu John S | ▲ Buy | Grant | 190,840 | $0 | 10/8/2025 |
| Bae Hyun W. | ▲ Buy | Grant | 10,000 | $0 | 9/16/2025 |
| Keyoung Hansoo Michael | ▲ Buy | Grant | 10,000 | $0 | 9/16/2025 |
| Murali Ramachandran | ▲ Buy | Grant | 14,000 | $0 | 1/1/2025 |
| Yu John S | ▲ Buy | Grant | 14,000 | $0 | 1/1/2025 |
| Bhowmick Neil | ▲ Buy | Grant | 14,000 | $0 | 1/1/2025 |
| Murali Ramachandran | ▲ Buy | Open Market | 200 | $318 | 11/25/2024 |
| Samuelson Doug | ▲ Buy | Open Market | 2,500 | $4K | 11/22/2024 |
| Yu John S | ▲ Buy | Open Market | 4,000 | $6K | 11/20/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Kairos Pharma Reports Positive Phase 2 Data for ENV-105
Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.
Kairos Pharma Reports Positive Phase 2 Data for ENV-105. Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.